# A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

> **NCT01147861** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 39 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK256073
- **DRUG:** GSK256073
- **DRUG:** GSK256073
- **DRUG:** GSK256073
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01147861
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2010-09-07
- **Final completion:** 2010-09-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147861, "A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01147861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*